U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937593) titled 'A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954' on April 09.
Brief Summary: The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of VIS954 compared with placebo in healthy adult participants.
Study Start Date: March 13
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: VIS954
A humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
DRUG: Placebo
VIS954 Placebo
Recruitment Status: RECRUITING
Sponsor: Visterra, Inc.
Published by HT Digital Content Services with permission from Health Dail...